Groundbreaking research in the field of gene and cell therapy will be presented at the ESGCT annual congress. With more than 2,500 attendees in 2023, the meeting is growing year on year and demonstrates the importance of gene therapy in the development of treatments for various diseases. The meeting attracts delegates from around the world and provides an opportunity to network and meet existing colleagues and collaborators. Over 100 world-leading experts will present their latest research findings – from scientists working at the forefront of the field to Nobel Prize winners. This year, the conference will take place in one of Rome’s most famous buildings, La Nuvola in the EUR architectural district.
As the leading preclinical CRO in Europe, we will be presenting our full range of gene therapy services at the event. The Scantox Group has built a significant reputation in gene therapy research and preclinical lead optimization over the past decades. By leveraging scientific expertise and a flexible service model, our company has remained at the forefront of innovation, providing customized solutions to meet the evolving needs of a diverse client base.
Scantox services support a broad range of preclinical study elements. More than 100 successfully completed in vitro and in vivo gene therapy studies using cell therapy, AAVs, lentiviruses, ASOs and siRNAs reflect our expertise in conducting gene therapy studies. This enables our clients to advance their in vitro and in vivo gene therapy projects under one roof in a trustful collaboration based on the highest technical and scientific standards. Meet us at ESGCT 2024 and learn more!
